BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Treatment
640 results:

  • 1. Binimetinib in combination with nivolumab or nivolumab and ipilimumab in patients with previously treated microsatellite-stable metastatic colorectal cancer with RAS mutations in an open-label phase 1b/2 study.
    Elez E; Cubillo A; Alfonso PG; Middleton MR; Chau I; Alkuzweny B; Alcasid A; Zhang X; Van Cutsem E
    BMC Cancer; 2024 Apr; 24(1):446. PubMed ID: 38600471
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
    Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
    Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
    Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
    Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
    Kim JW; Lee HJ; Lee JY; Park SR; Kim YJ; Hwang IG; Kyun Bae W; Byun JH; Kim JS; Kang EJ; Lee J; Shin SJ; Chang WJ; Kim EO; Sa JK; Park KH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38485184
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Intratumoral injection of interferon gamma promotes the efficacy of anti-pd1 treatment in colorectal cancer.
    Tang Y; Wei J; Ge X; Yu C; Lu W; Qian Y; Yang H; Fu D; Fang Y; Zhou X; Wang Z; Xiao Q; Ding K
    Cancer Lett; 2024 Apr; 588():216798. PubMed ID: 38467181
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Efficacy and safety of pd-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study.
    Yang Z; Gao J; Zheng J; Han J; Li A; Liu G; Sun Y; Zhang J; Chen G; Xu R; Zhang X; Liu Y; Bai Z; Deng W; He W; Yao H; Zhang Z
    Signal Transduct Target Ther; 2024 Mar; 9(1):56. PubMed ID: 38462629
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
    Khushalani NI; Ott PA; Ferris RL; Cascone T; Schadendorf D; Le DT; Sharma MR; Barlesi F; Sharfman W; Luke JJ; Melero I; Lathers D; Neely J; Suryawanshi S; Sanyal A; Holloway JL; Suryawanshi R; Ely S; Segal NH
    J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458639
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. TMEM160 promotes tumor immune evasion and radiotherapy resistance via PD-L1 binding in colorectal cancer.
    Dai X; Wu Z; Ruan R; Chen J; Huang C; Lei W; Yao Y; Li L; Tang X; Xiong J; Feng M; Deng J
    Cell Commun Signal; 2024 Mar; 22(1):168. PubMed ID: 38454413
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-pd-1 therapy efficacy against colorectal cancer.
    Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
    Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Unveiling the immune symphony: decoding colorectal cancer metastasis through immune interactions.
    He R; Huang S; Lu J; Su L; Gao X; Chi H
    Front Immunol; 2024; 15():1362709. PubMed ID: 38415252
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Lovastatin/SN38 co-loaded liposomes amplified ICB therapeutic effect via remodeling the immunologically-cold colon tumor and synergized stimulation of cGAS-STING pathway.
    Yang Y; Qi J; Hu J; Zhou Y; Zheng J; Deng W; Inam M; Guo J; Xie Y; Li Y; Xu C; Deng W; Chen W
    Cancer Lett; 2024 Apr; 588():216765. PubMed ID: 38408604
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Magnetic resonance imaging-based approaches for detecting the efficacy of combining therapy following VEGFR-2 and pd-1 blockade in a colon cancer model.
    Xu X; Ma M; Ye K; Zhang D; Chen X; Wu J; Mo X; Xiao Z; Shi C; Luo L
    J Transl Med; 2024 Feb; 22(1):198. PubMed ID: 38395884
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Immune cell infiltrates in peritoneal metastases from colorectal cancer.
    Sundström P; Hogg S; Quiding Järbrink M; Bexe Lindskog E
    Front Immunol; 2024; 15():1347900. PubMed ID: 38384469
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. An innovative antibody fusion protein targeting PD-L1, VEGF and TGF-β with enhanced antitumor efficacies.
    Fan W; Chen Y; Zhou Z; Duan W; Yang C; Sheng S; Wang Y; Wei X; Liu Y; Huang Y
    Int Immunopharmacol; 2024 Mar; 130():111698. PubMed ID: 38377856
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Machine learning-based extrachromosomal DNA identification in large-scale cohorts reveals its clinical implications in cancer.
    Wang S; Wu CY; He MM; Yong JX; Chen YX; Qian LM; Zhang JL; Zeng ZL; Xu RH; Wang F; Zhao Q
    Nat Commun; 2024 Feb; 15(1):1515. PubMed ID: 38373991
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. BAMLET administration via drinking water inhibits intestinal tumor development and promotes long-term health.
    Tran HT; Wan MLY; Ambite I; Cavalera M; Grossi M; Háček J; Esmaeili P; Carneiro ANBM; Chaudhuri A; Ahmadi S; Svanborg C
    Sci Rep; 2024 Feb; 14(1):3838. PubMed ID: 38360830
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. ImmuneMirror: A machine learning-based integrative pipeline and web server for neoantigen prediction.
    Chuwdhury GS; Guo Y; Chiang CL; Lam KO; Kam NW; Liu Z; Dai W
    Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343325
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Progress of pd-1/PD-L1 inhibitor combination therapy in immune treatment for HER2-positive tumors.
    Zhao S; Qiu Y; Yuan M; Wang Z
    Eur J Clin Pharmacol; 2024 May; 80(5):625-638. PubMed ID: 38342825
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High colorectal cancer: A Preliminary Report of Case Series.
    Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
    Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 32.